Literature DB >> 1703517

Selective alterations in natural killer cell subsets in patients with atopic dermatitis.

W Wehrmann1, U Reinhold, S Kukel, N Franke, M Uerlich, H W Kreysel.   

Abstract

We examined the immunophenotypic characteristics of natural killer (NK) cell subsets in patients with severe atopic dermatitis (AD), rhinitis allergica (RA) and in healthy controls. Expression of CD16, CD56 and CD57 antigens on peripheral blood lymphocytes was evaluated by simultaneous double immunocytofluorometry. Our results showed significantly lower percentages of cells with CD16, CD56 and CD57 surface antigens in patients with AD. Furthermore subdivision of the AD group into two subgroups, AD1 and AD0 (with and without antigen-specific IgE antibodies against potent inhalative allergens, i.e. mite, grass, rye, birch, cat) revealed that patients of subgroup AD1 showed a more prominent decrease compared to that of subgroup AD0. Moreover, we found a significant negative correlation between the percentage of CD56 + CD16 + NK cells and total IgE levels in serum, which were significantly higher in patients of subgroup AD1 than in AD0. NK cell activity was deficient in patients with AD but there was no difference between both subgroups. These data indicate that considerable heterogeneity in immunologic regulation may exist in patients with AD with regard to their NK cell subsets.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703517     DOI: 10.1159/000235196

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  8 in total

1.  Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis.

Authors:  Madison R Mack; Jonathan R Brestoff; Melissa M Berrien-Elliott; Anna M Trier; Ting-Lin B Yang; Matthew McCullen; Patrick L Collins; Haixia Niu; Nancy D Bodet; Julia A Wagner; Eugene Park; Amy Z Xu; Fang Wang; Rebecca Chibnall; M Laurin Council; Carrie Heffington; Friederike Kreisel; David J Margolis; David Sheinbein; Paola Lovato; Eric Vivier; Marina Cella; Marco Colonna; Wayne M Yokoyama; Eugene M Oltz; Todd A Fehniger; Brian S Kim
Journal:  Sci Transl Med       Date:  2020-02-26       Impact factor: 17.956

2.  Different natural killer (NK) receptor expression and immunoglobulin E (IgE) regulation by NK1 and NK2 cells.

Authors:  E Aktas; M Akdis; S Bilgic; R Disch; C S Falk; K Blaser; C Akdis; G Deniz
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 3.  The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.

Authors:  Chris Fraker; Allison L Bayer
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

4.  Reduced interferon-gamma (IFN-gamma) secretion with increased IFN-gamma mRNA expression in atopic dermatitis: evidence for a post-transcriptional defect.

Authors:  M L Tang; G Varigos; A S Kemp
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

Review 5.  Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics.

Authors:  A L Bosma; A Ascott; R Iskandar; K Farquhar; J Matthewman; M W Langendam; A Mulick; K Abuabara; H C Williams; P I Spuls; S M Langan; M A Middelkamp-Hup
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-02-25       Impact factor: 9.228

Review 6.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.

Authors:  Carolyn M Nielsen; Matthew J White; Martin R Goodier; Eleanor M Riley
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

7.  Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases.

Authors:  Nicola Antonucci; Alessandra Cirillo; Dario Siniscalco
Journal:  Case Rep Psychiatry       Date:  2015-09-29

8.  CD1dhiPD-L1hiCD27+ Regulatory Natural Killer Subset Suppresses Atopic Dermatitis.

Authors:  Keun Young Min; Jimo Koo; Geunwoong Noh; Dajeong Lee; Min Geun Jo; Ji Eon Lee; Minseong Kang; Seung Yeun Hyun; Wahn Soo Choi; Hyuk Soon Kim
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.